Pacira BioSciences, Inc.

PCRXNASDAQHealthcare● Active

$22.86

+$0.11(+0.48%)

Market Cap$899198100

P/E Ratio—

52W High$27.64

52W Low$18.8

Avg Volume611K

Open$22.70

Beta0.29

Free Cash Flow Financials Revenue

Pacira BioSciences, Inc. (PCRX) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

PCRX · free cash flow · updated Jun 8, 2026

Core FCF metrics

PCRX · FCF · TTM · margin & CAGR

Free cash flow was $136.7M for FY2025 (fiscal year ending 2025-12-31), down 23.5% year-over-year The FCF margin was 18.8%. Five-year CAGR stands at +28.4%.

FY2025 Free Cash Flow$136.7M▼ -23.5% YoY

Trailing 12M (TTM)$132.7Mtrailing 4 quarters sum

FCF Margin18.8%$136.7M ÷ revenue

3-Year CAGR+5.9%FY2022 → FY2025

5-Year CAGR+28.4%FY2020 → FY2025

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

PCRX · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest$152.0M(15M)$136.7M▼ 23.5%18.8%

FY2024$189.4M(11M)$178.8M▲ +28.1%25.5%

FY2023$154.6M(15M)$139.5M▲ +21.1%20.7%

FY2022$145.3M(30M)$115.2M▲ +44.3%17.3%

FY2021$125.7M(46M)$79.9M▲ +103.5%14.8%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

PCRX · P/FCF · FCF yield · FCF per share

Pacira BioSciences, Inc. (PCRX) trades at a FCF yield of 14.76% and a price-to-free-cash-flow ratio of 7.7x. FCF per share stands at $2.98, calculated using trailing twelve-month FCF divided by basic weighted-average shares outstanding.

FCF Yield (TTM)

14.76%

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

$2.98

TTM FCF ÷ Shares Outstanding

Price / FCF

x7.7

Share Price ÷ FCF per Share

EV / FCF (TTM)

x8.8

Enterprise Value basis

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

PCRX · cash flow statement · operating / investing / financing

For FY2025, Pacira BioSciences, Inc. generated $152.0M in operating cash flow and spent 15M in capital expenditures, yielding $136.7M in free cash flow.

Operating Activities

+$152.0M

Cash from core business operations

2025-12-31

Investing Activities

+$99.5M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$369.6M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF ($152.0M) − |CapEx| (15M) = FCF ($136.7M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

PCRX vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Pacira BioSciences, Inc.YOU

PCRX

$136.7M-23.5%18.8%

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Pacira BioSciences, Inc. (PCRX) reported free cash flow of $136.7M for FY2025 (fiscal year ending 2025-12-31), down 23.5% year-over-year. The FCF margin was 18.8%.

Based on available data, Pacira BioSciences, Inc. has maintained positive free cash flow for at least 10 fiscal year(s). FCF peaked at $178.8M in FY2024. The 5-year CAGR stands at +28.4%.

Pacira BioSciences, Inc.'s FCF yield is 14.76% and price-to-FCF ratio is 7.7x for FY2025, based on the latest available data.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

PCRX free cash flow · 8 questions

Pacira BioSciences, Inc. free cash flow was $136.7M for FY2025, down 23.5% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at $132.7M.

PCRX free cash flowPCRX FCFPCRX FCF 2025PCRX free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Pacira BioSciences, Inc. · Pacira BioSciences, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026